Aethlon Medical to Be Acquired by North Immunology in Reverse Merger

What happened

Aethlon Medical, Inc. (Nasdaq: AEMD) disclosed in a Form 8-K filed September 17, 2026 that it entered an Agreement and Plan of Merger and Reorganization with North Immunology, Inc., a private Delaware corporation, along with two newly created Aethlon subsidiaries named Nighthawk Merger Sub Corp. and Nighthawk Second Merger Sub, LLC.

Under the deal, the first subsidiary merges into North Immunology, which survives as an Aethlon subsidiary; immediately afterward North Immunology merges into the second subsidiary. The filing describes the transaction as intended to qualify as a tax-free reorganization under Section 368(a) of the Internal Revenue Code.

The exchange ratio is built from a valuation framework in the agreement that assigns North Immunology an equity value of $150 million — or a higher figure if the concurrent private placement implies one — and Aethlon a value of $16.5 million, reduced by any shortfall in Aethlon's net cash at closing below $0. On that basis, the filing states pre-merger North Immunology stockholders, including private-placement investors, are expected to own roughly 95.25% of the combined company and pre-merger Aethlon stockholders roughly 4.75%. The percentages include 591,574 Aethlon shares to be issued to Maxim before closing for advisory fees.

The combined company is to be led by North Immunology's chief executive officer, and the directors and officers of Aethlon and the surviving entity following closing are to be designated by North Immunology. Aethlon will ask stockholders to approve the share issuance, the resulting change of control, and charter amendments that would rename the company "North Immunology, Inc.," effect a reverse stock split if needed for Nasdaq listing standards, and increase authorized shares.

The financing

Simultaneously with the merger agreement, institutional and accredited investors signed a securities purchase agreement with North Immunology to buy North Immunology common stock and pre-funded warrants for about $180 million — about $146 million in cash and about $34 million from converting North Immunology convertible promissory notes plus accrued interest. North Immunology's outstanding simple agreements for future equity, or SAFEs, convert into its common stock before closing.

Receipt by North Immunology of at least $175 million from that placement is a condition to closing the merger. The filing does not say why North Immunology or Aethlon chose to structure the deal this way, and no other reason is given in the sources.

Support agreements, lock-ups and a CVR

Certain Aethlon officers and directors, in their capacity as stockholders, signed support agreements agreeing to vote for the merger and against alternatives; certain North Immunology officers, directors and stockholders holding the requisite vote signed equivalent agreements. Certain North Immunology holders also agreed not to transfer the Aethlon shares they receive for 180 days after closing.

Before the first merger takes effect, Aethlon may distribute one contingent value right, or CVR, per outstanding share of common and preferred stock. Each CVR is a contractual right to net proceeds, if any, from selling, licensing, transferring or otherwise monetizing Aethlon's pre-merger legacy business, including its Hemopurifier assets. The CVRs are not registered with the SEC, carry no voting or dividend rights, represent no equity or ownership interest, accrue no interest, and are not transferable except in limited circumstances; if no proceeds are received, holders get nothing, and the filing states there can be no assurance any payment will be made.

Market reaction

Aethlon shares closed at $6.92 on September 17, 2026, up 383.92% from the prior close of $1.43, according to the price data. Volume was 80,847,027 shares against an average of about 1,109,962 — roughly 72.8 times normal, a z-score of 13.06. All explanation for the move comes from the filing; the price data alone does not assign a cause.

What this means

A Form 8-K is the current report a US public company must file with the SEC when certain specified events occur — here, Items 1.01 (entry into a material definitive agreement), 5.01 (a change in control), 7.01 (Regulation FD disclosure) and 9.01 (financial statements and exhibits). It is a disclosure obligation, not a request for anyone's approval.

This particular deal is a reverse merger: a private company, North Immunology, is folded into a public one so that North Immunology's business ends up inside a Nasdaq-listed shell. The mechanical tell is the ownership split. Because the combined company's shares go overwhelmingly to North Immunology holders — about 95.25% — control passes to them even though Aethlon is the listed entity. The two-step structure, with one merger immediately following the other, exists so the surviving entity ends up as an Aethlon subsidiary rather than the reverse. The name change to "North Immunology, Inc." and the possible reverse stock split, in which existing shares are consolidated to lift the per-share price to satisfy Nasdaq's minimum, are the usual housekeeping of this structure.

The pre-funded warrants matter because of a technical rule. Under Section 13(d) of the Exchange Act, a holder crossing a set ownership threshold has to make filings and is treated as a beneficial owner; to let large placement investors take big positions without tripping that threshold, the deal issues warrants that give the economic exposure of stock without counting toward the limit. The filing says this is exactly what happens: holders get shares up to their beneficial ownership limitation and pre-funded warrants for the excess.

A CVR is a contractual promise to pass through future money from assets the buyer does not want. Here it covers Aethlon's legacy Hemopurifier business. It is not stock and is not registered, so it cannot be bought or sold like shares — it is closer to a claim on whatever sale proceeds materialize, and the filing warns those may be zero. The Hemopurifier is a blood-filtration device Aethlon has been developing; because the CVR is tied to the whole legacy business rather than a single defined sale, the timing and size of any payout are not stated.

In a merger, both sides breach nothing but cannot close until conditions are met. This agreement sets a long-stop date of June 17, 2027, subject to extension, and termination fees: $300,000 payable by Aethlon to North Immunology and $2,000,000 payable by North Immunology to Aethlon if the deal is terminated in specified circumstances. Closing also requires the Form S-4 registration statement to become effective, Hart-Scott-Rodino antitrust waiting periods to expire or terminate, Nasdaq to approve an initial listing application, and both sets of stockholders to approve. Aethlon must file the Form S-4, which combines a registration statement with the proxy statement for the stockholder vote — one document serving both securities registration and shareholder-solicitation duties.

The filing does not state why Aethlon and North Immunology agreed to these terms, and the sources give no other explanation.